Süleyman BÜYÜKBERBER, Banu ÖZTÜRK, Mehmet CİNDORUK, Emel YAMAN, Ali Osman KAYA, Uğur COŞKUN, Mustafa BENEKLİ, Ramazan YILDIZ

Eroziv gastritlerde CA 19-9, CEA ve CA 72-4 düzeyleri

Amaç: Bu çalışmanın amacı eroziv gastritli malignite dışlanmış hastalarda serumCEA, CA 19-9 ve CA 72-4 düzeylerinin önemini araştırmaktır. Gereç ve Yöntem: Özofagogastroduodenoskopi yapılan ve eroziv gastrit tespit edi- len hastalarda tümör markır bakılmış olan 40 (12 erkek, 28 kadın) hasta değerlendirildi. Bulgular: Dört hastada CA 19-9 yüksekliği tespit edildi (1. hasta: 593,3 U/ml; 2.hasta: 75,8 U/ml; 3. hasta: 49,9 U/ml; 4. hasta: 44,8 U/ml). CEA yüksekliği ve CA72-4 yüksekliği de birer hastada tespit edildi (6,33 ng/ml ve 5,42 U/ml). Diğer hastalardaki CA 19-9 ortalaması 8,12±8,18 U/ml, CEA ortalaması: 1,67±0,93 ng/ml veCA 72-4 ortalaması: 1,64±1,05 U/ml olarak bulundu. Sonuç: Her ne kadar tanısal olmasa da eroziv gastrit de tümör markır yüksekliğininolası sebeplerinden birisi olabilir.

The levels of CA 19-9, CEA, and CA 72-4 in erosive gastritis

Purpose: To investigate the clinical significance of serum CEA, CA 19-9, and CA72-4 levels in patients with erosive gastritis in whom malignancy was ruled out. Materials and Methods: Forty patients (12 males, 28 females) diagnosed with ero- sive gastritis by esophagogastroduodenoscopy and having measured tumor markerlevels were assessed. Results: Increased CA 19-9 level was reported in 4 patients (patient 1: 593.3 U/ml;patient 2: 75.8 U/ml; patient 3: 49.9 U/ml; patient 4: 44.8 U/ml). CEA and CA 72-4levels increased in one patient, 6.33 ng/ml and 5.42 U/ml, respectively. The mean ofthese markers for the other patients were as follows: CA 19-9: 8.12±8.18 U/ml, CEA:1.67±0.93 ng/ml, and CA 72-4: 1.64±1.05 U/ml. Conclusion: Although it was not diagnostic, erosive gastritis may be another causeof tumor marker elevation.

PDF

___

1. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 1997; 4: 380-387.
2. Kirkwood KS, Khitin LM, Barwick KW. Prognostic indicators for cancer. Gastric cancer. Surg Oncol Clin N Am 1997; 6: 495-514.
3. Micali B, Florio MG, Venuti A, et al. Usefulness of carcinoembryonic antigen measurement in gastric juice of patients with gastric disorders. J Clin Gastroenterol 1983; 5: 411-415.
4. Piantino P, Taccone W, Fusaro A, et al. Signifcance of CA 72.4 serum levels in gastrointestinal diseases. Int J Biol Markers 1990; 5: 77-80.
5. Muretto P, Graziano F, Staccioli MP, et al. An endogastric capsule for measuring tumor markers in gastric juice: an evaluation of the safety and effcacy of a new diagnostic tool. Ann Oncol 2003; 14: 105-109.
6. Duraker N, Naci Celik A, Gencler N. The prognostic signifcance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients. Eur J Surg Oncol 2002; 28: 844-849.
7. Harrison JD, Stanley J, Morris DL. CEA and CA 19.9 in gastric juice and serum: an aid in the diagnosis of gastric carcinoma? Eur J Surg Oncol 1989; 15: 253-257.
8. Satake K, Yamashita K, Kitamura T, et al. Carcinoembryonic anti- gen-like activity in gastric juice and plasma in patients with gastric disorders. Am J Surg 1980; 139: 714-718.
9. Tocchi A, Costa G, Lepre L, et al. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol 1998; 124: 450-455.
10. Kojima O, Tanioku T, Kitagawa N, et al. Immunoreactive carcinoembryonic antigen in gastric juice in patients with gastric cancer. Jpn J Surg 1983; 13: 324-330.
11. Farinati F, Nitti D, Cardin F, et al. CA 19-9 determination in gastric juice: role in identifying gastric cancer and high risk patients. Eur J Cancer Clin Oncol 1988; 24: 923-927.